News & Events

Abcam enables faster drug and biomarker discovery with immunoassay research suite

Abcam enables faster drug and biomarker discovery with immunoassay research suite

Cambridge UK, 12 April 2016: Abcam plc, a global leader in the supply of life science research tools, today announced the launch of a suite of immunoassay products based on its recombinant, monoclonal antibody pairs, as part of its commitment to deliver quality reagents to life science researchers at scale.

Matched antibody pairs are central to enzyme-linked immunoabsorbant assays (ELISAs), which are widely used to study secreted biomarkers, and are fundamental to research in areas such as immunology and cancer. Abcam optimises its antibody pairs to avert the reproducibility and scalability challenges previously faced by researchers, which can cause variability in results. Abcam’s matched antibody pairs use recombinant monoclonal antibody technology, such as the patented RabMAb® technology, to provide improved consistency over polyclonal antibodies. The pairs are screened for sensitive performance and rigorously tested in a variety of complex sample types including plasma, serum and cell lysates.

These optimised pairs are already part of Abcam’s SimpleStep ELISA® kits, and will now be available as stand-alone matched antibody pair kits. The new stand-alone high volume format provides greater flexibility to researchers and facilitates cost-effective drug discovery, by enabling scale up from small pilot studies to large-scale high-throughput assay platforms.

Alejandra Solache, Head of Production, Development and Manufacturing at Abcam, said: “By providing researchers with highly optimised matched antibody pairs in a stand-alone format, we’re enabling scale up to higher-throughput assay platforms and faster drug discovery. Our recombinant monoclonal antibody pairs are inherently reproducible, providing reliable results the first time as well as supporting long-term use.”

To find out more, visit:

Notes To Editors

About Abcam
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Two-thirds of the world’s 750,000 life science researchers use Abcam’s affinity binders, reagents, biomarkers and assays and the company’s products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam’s ten offices are located in the world’s leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company now employs over 800 people and sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit and

Issued for and on behalf of Abcam by Instinctif Partners.
For more information please contact:

Francesca Axe
T: +44 (0) 1223 696000

Media enquiries
Tim Watson / Dr. Lynne Trowbridge

Instinctif Partners
T: +44 (0) 20 7866 7861 / +44 (0) 20 7457 2861

back to news


Tim WatsonPartner